Intensive supportive care plus immunosuppression in IgA nephropathy

New England Journal of Medicine

Volumn 373, Issue 23, 2015, Pages 2225-2236

  Rauen, Thomas ^a   Eitner, Frank ^a,b   Fitzner, Christina ^a   Sommerer, Claudia ^c   Zeier, Martin ^c   Otte, Britta ^d   Panzer, Ulf ^e   Peters, Harm ^f   Benck, Urs ^g   Mertens, Peter R ^h   Kuhlmann, Uwe ⁱ   Witzke, Oliver ^j   Gross, Oliver ^k   Vielhauer, Volker ^l   Mann, Johannes F E ^m   Hilgers, Ralf Dieter ^a   Floege, Jürgen ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b BAYER PHARMA AG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h OTTO VON GUERICKE UNIVERSITY   (Germany)

ⁱ Bremen North Hospital   (Germany)

^j UNIVERSITY HOSPITAL ESSEN   (Germany)

^k UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^l LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^m Munich General Hospital   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PREDNISOLONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; GASTROINTESTINAL INFECTION; GLOMERULUS FILTRATION RATE; HEMATURIA; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; IMPAIRED GLUCOSE TOLERANCE; INFECTION; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SEPSIS; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN; ADULT; ADVERSE EFFECTS; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; GLOMERULONEPHRITIS, IGA; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STATISTICAL MODEL; TREATMENT FAILURE;

ADULT; ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COMBINED MODALITY THERAPY; CRITICAL CARE; FEMALE; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, IGA; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSION; LOGISTIC MODELS; MALE; MIDDLE AGED; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM; TREATMENT FAILURE;

EID: 84948798394     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1415463     Document Type: Article

References (33)

1. Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med 2013; 368: 2402-14.
2. Floege J. The pathogenesis of IgA nephropathy: what is new and how does it change therapeutic approaches? Am J Kidney Dis 2011; 58: 992-1004.
3. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl2012; 2: 142. abstract.
4. Coppo R, Peruzzi L, Amore A, et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 2007; 18: 1880-8.
5. Praga M, Gutiérrez E, González E, Morales E, Hernández E. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 2003; 14: 1578-83.
6. Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 1999; 353: 883-7.
7. Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004; 15: 157-63.
8. Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 2009; 24: 3694-701.
9. Lv J, Zhang H, Chen Y, et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis 2009; 53: 26-32.
10. Eitner F, Floege J. Glomerular disease: ACEIs with or without corticosteroids in IgA nephropathy? Nat Rev Nephrol 2010; 6: 252-4.
11. Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002; 13: 142-8.
12. Floege J, Feehally J. Treatment of IgA nephropathy and Henoch-Sch.nlein nephritis. Nat Rev Nephrol 2013; 9: 320-7.
13. Eitner F, Ackermann D, Hilgers RD, Floege J. Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol. J Nephrol 2008; 21: 284-9.
14. Parikh SV, Haddad NJ, Hebert LA. Retarding progression of kidney disease. In: Freehally J, Johnson RJ, Floege J, eds. Comprehensive clinical nephrology. 5th ed. St. Louis: Saunders, 2015: 931-41.
15. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-56.
16. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975; 31: 103-15.
17. International Conference on Harmonisation E9 Expert Working Group. ICH harmonised tripartite guideline: statistical principles for clinical trials. Stat Med 1999; 18: 1905-42.
18. Phillips A, Fletcher C, Atkinson G, et al. Points to consider on multiplicity issues in clinical trials. Pharm Stat 2002; 12: 255-9.
19. Ruggenenti P, Perticucci E, Cravedi P, et al. Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol 2008; 19: 1213-24.
20. Yoshikawa N, Ito H, Sakai T, et al. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. J Am Soc Nephrol 1999; 10: 101-9.
21. Yoshikawa N, Honda M, Iijima K, et al. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol 2006; 1: 511-7.
22. Shima Y, Nakanishi K, Hama T, et al. Spontaneous remission in children with IgA nephropathy. Pediatr Nephrol 2013; 28: 71-6.
23. Levey AS, Inker LA, Coresh J. GFR estimation: from physiology to public health. Am J Kidney Dis 2014; 63: 820-34.
24. Coresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 2014; 311: 2518-31.
25. Reich HN, Troyanov S, Scholey JW, Cattran DC. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 2007; 18: 3177-83.
26. Tesar V, Troyanov S, Bellur S, et al. Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study. J Am Soc Nephrol 2015; 26: 2248-58.
27. Nam KH, Kie JH, Lee MJ, et al. Optimal proteinuria target for renoprotection in patients with IgA nephropathy. PLoS One 2014; 9(7): e101935.
28. Kim JK, Kim JH, Lee SC, et al. Clinical features and outcomes of IgA nephropathy with nephrotic syndrome. Clin J Am Soc Nephrol 2012; 7: 427-36.
29. Lv J, Yang Y, Zhang H, et al. Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study. J Am Soc Nephrol 2013; 24: 2118-25.
30. Kanno Y, Okada H, Saruta T, Suzuki H. Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up. Clin Nephrol 2000; 54: 360-5.
31. Pozzi C, Andrulli S, Pani A, et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol 2010; 21: 1783-90.
32. Lv J, Zhang H, Cui Z, Su T, Zhang Y, Wang H. Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy. Nephrol Dial Transplant 2008; 23: 2868-72.
33. Tang SC, Tang AW, Wong SS, Leung JC, Ho YW, Lai KN. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int 2010; 77: 543-9.